BioCentury
ARTICLE | Clinical News

CSL112: Phase I data

December 3, 2012 8:00 AM UTC

A double-blind, placebo-controlled, Australian Phase I trial in 36 healthy volunteers showed that CSL112 was well tolerated with no treatment-related adverse events reported. The most common adverse e...